Australia's most trusted
source of pharma news
Tuesday, 14 April 2026
Posted 14 April 2026 PM
A growing number of pharmas have joined the race to “reinvent weight loss” with the lucrative market projected to reach AU$210-billion-plus (US$150 billion) by 2035, according to Clarivate.
The analytics company named 16 promising GLP-1 RAs candidates in development to treat obesity, either alone or in combination with other RAs in its Drugs to Watch 2026 report, noting the “growing appetite” for next-generation therapies.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.